Literature DB >> 35345814

Hematological Changes in the Second Wave of SARS-CoV-2 in North India.

Akanksha Singh1, Shailendra P Verma2, Rashmi Kushwaha1, Wahid Ali1, Himanshu D Reddy3, Uma S Singh1.   

Abstract

Background COVID-19 is a rapidly spreading pandemic caused by SARS-CoV-2. India experienced a second wave peak in mid of April 2021, and it emerged as a medical crisis. This study was taken up to show if the hematological and peripheral blood changes can be used as a readily available tool to demarcate the patients needing ICU care so that the ICU can be utilized more prudently.  Material and method One hundred reverse transcription-polymerase chain reaction (RT-PCR) confirmed cases of COVID-19, 50 each from ICU and non-ICU wards, were included in this observational study. At the time of admission blood sample was collected for evaluation of hematological parameters. Results We noted that 74% of patients admitted in ICU were males and 28% were more than 60 years of age. In ICU patients, the absolute neutrophil count (ANC) was significantly raised when compared to non-ICU cases (p=0.023). The nadir absolute lymphocyte count (ALC) was 0.11x109/L in ICU patients and 0.95x109/L in non-ICU patients. There was a significant increase in neutrophil-lymphocyte ratio (NLR; p<0.001) in ICU patients with a proposed cut-off value of 7.73. Platelet-lymphocyte ratio (PLR) was also raised in ICU patients; however, this increase was not significant (p= 0.623). The proposed cut-off value of PLR is 126.73. A significant reduction in a lymphocyte-monocyte ratio (LMR) was observed in ICU patients when compared to non-ICU cases (p<0.001). Thrombocytopenia was more commonly seen in ICU patients; however, this was not statistically significant. Viral-induced cytopathic effects like plasmacytoid lymphocytes with cytoplasmic granules, the presence of toxic changes in neutrophils, and large-sized platelets were commonly observed in ICU patients. Conclusion Our results suggest that hematological parameters like ANC, absolute lymphocyte count (ALC), platelet count, NLR, PLR, and peripheral smear changes are simple assessment factors that can serve as indicators for the severity of COVID-19 and will demarcate the patients who need ICU-care. This will help in the judicious use of ICU facilities for patients who are actually in need.
Copyright © 2022, Singh et al.

Entities:  

Keywords:  covid-19 hematological changes; covid-19 india; covid-19 induced cytopathic changes; neutrophil-to-lymphocyte ratio (nlr); platelet-to-lymphocyte ratio (plr); sars-cov-2 infection; second wave of covid-19

Year:  2022        PMID: 35345814      PMCID: PMC8956484          DOI: 10.7759/cureus.23495

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  20 in total

Review 1.  Thrombocytopenia in patients with severe acute respiratory syndrome (review).

Authors:  Mo Yang; Margaret H L Ng; Chi Kong Li
Journal:  Hematology       Date:  2005-04       Impact factor: 2.269

2.  [Death risk factors of severe acute respiratory syndrome with acute respiratory distress syndrome].

Authors:  Wei-qun He; Si-bei Chen; Xiao-qing Liu; Yi-min Li; Zheng-lun Xiao; Nan-shan Zhong
Journal:  Zhongguo Wei Zhong Bing Ji Jiu Yi Xue       Date:  2003-06

3.  The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks.

Authors:  Giuseppe Lippi; Mario Plebani
Journal:  Clin Chem Lab Med       Date:  2020-06-25       Impact factor: 3.694

4.  Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.

Authors:  Chuan Qin; Luoqi Zhou; Ziwei Hu; Shuoqi Zhang; Sheng Yang; Yu Tao; Cuihong Xie; Ke Ma; Ke Shang; Wei Wang; Dai-Shi Tian
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

6.  Atypical lymphocyte morphology in SARS-CoV-2 infection.

Authors:  Siraj M El Jamal; Christian Salib; Aryeh Stock; Norlita I Uriarte-Haparnas; Benjamin S Glicksberg; Julie Teruya-Feldstein; Francine R Dembitzer; Girish N Nadkarni; Adolfo Firpo-Betancourt
Journal:  Pathol Res Pract       Date:  2020-06-10       Impact factor: 3.250

Review 7.  Hematological Abnormalities in COVID-19: A Narrative Review.

Authors:  Asma Rahman; Roshan Niloofa; Umesh Jayarajah; Sanjay De Mel; Visula Abeysuriya; Suranjith L Seneviratne
Journal:  Am J Trop Med Hyg       Date:  2021-02-19       Impact factor: 2.345

8.  Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study.

Authors:  Xisheng Yan; Fen Li; Xiao Wang; Jie Yan; Fen Zhu; Shifan Tang; Yingzhong Deng; Hua Wang; Rui Chen; Zhili Yu; Yaping Li; Jingzhou Shang; Lingjun Zeng; Jie Zhao; Chaokun Guan; Qiaomei Liu; Haifeng Chen; Wei Gong; Xin Huang; Yu-Jiao Zhang; Jianguang Liu; Xiaoyan Dong; Wen Zheng; Shaoping Nie; Dongsheng Li
Journal:  J Med Virol       Date:  2020-06-09       Impact factor: 20.693

9.  Hematological findings and complications of COVID-19.

Authors:  Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Ismail Elalamy; Efstathios Kastritis; Theodoros N Sergentanis; Marianna Politou; Theodora Psaltopoulou; Grigoris Gerotziafas; Meletios A Dimopoulos
Journal:  Am J Hematol       Date:  2020-05-23       Impact factor: 13.265

Review 10.  Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic.

Authors:  Sue Pavord; Jecko Thachil; Beverley J Hunt; Mike Murphy; Gillian Lowe; Mike Laffan; Mike Makris; Adrian C Newland; Drew Provan; John D Grainger; Quentin A Hill
Journal:  Br J Haematol       Date:  2020-06-02       Impact factor: 8.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.